Federal Register #C-533-884

Final Results of Trade Remedy Reviews for Glycine from India and MSG from China

This notice summarizes the final results of trade remedy administrative reviews conducted by the U.S. Department of Commerce, International Trade Administration: - Government Buyer: - U.S. Department of Commerce, International Trade Administration, Enforcement and Compliance - OEMs and Vendors Mentioned: - Kumar Industries, India (glycine producer/exporter) - Bajaj Healthcare Limited (glycine producer/exporter) - China-wide entity (for MSG) - Products/Services Reviewed: - Glycine from India - Countervailing duty administrative review for the 2023 calendar year - Final net countervailable subsidy rate: 45.33% ad valorem for Kumar Industries and Bajaj Healthcare Limited - Monosodium Glutamate (MSG) from China - Antidumping duty administrative review for November 2023 through October 2024 - China-wide entity subsidy rate: 56.54% - Notable Requirements and Details: - No specific product quantities or part numbers are listed, as this is a trade enforcement action, not a procurement solicitation - U.S. Customs and Border Protection is instructed to assess duties and collect cash deposits at the specified rates for future imports - Reviews include detailed methodologies and analyses of comments from interested parties

Description

The U.S. Department of Commerce has determined that countervailable subsidies were provided to certain producers and exporters of glycine from India during the period of review from January 1, 2023, through December 31, 2023. This notice announces the final results of the administrative review of countervailing duties for glycine imports from India. The review includes subsidy rate calculations for specific companies and instructions for cash deposits and assessments of countervailing duties. The final results are effective as of June 16, 2026.

View original listing